Merck’s Welireg receives European approval for two indications
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
This strategic partnership will also enable KIMS to exercise call option (not an obligation) to acquire majority stake in UAIMS Hospital in the coming years
Theatre (OTs) dedicated to cataract, LASIK, and retina treatments added to meet the growing demand
Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders
No safety signals related to the vaccine candidate were identified
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
The company has withdrawn all litigation against Vikas Lifecare Limited post withdrawal of the Alwar Case by VLL
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
Subscribe To Our Newsletter & Stay Updated